124276-67-1

Basic information

• Product Name: 1-(4-BROMOPHENYL)CYCLOPROPANECARBONITRILE, 97
• Synonyms: 1-(4-BROMOPHENYL)CYCLOPROPANECARBONITRILE, 97;1-(4-Bromophenyl)-1-cyanocyclopropane;1-(4-Bromophenyl)cyclopropane-1-carbonitrile;1-(4-Bromophenyl)-1-cyclopropanecarbonitrile;Cyclopropanecarbonitrile, 1-(4-bromophenyl)-
• CAS NO: 124276-67-1
• Molecular Formula: C₁₀H₈BrN
• Molecular Weight: 222.084
• Mol File: 124276-67-1.mol

Chemical Properties

• Melting Point: 84℃
• Boiling Point: 321.4°Cat760mmHg
• Flash Point: 148.2°C
• Appearance: /
• Density: 1.53
• Vapor Pressure: 0.000159mmHg at 25°C
• Refractive Index: 1.601
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 1-(4-BROMOPHENYL)CYCLOPROPANECARBONITRILE, 97(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(4-BROMOPHENYL)CYCLOPROPANECARBONITRILE, 97(124276-67-1)
• EPA Substance Registry System: 1-(4-BROMOPHENYL)CYCLOPROPANECARBONITRILE, 97(124276-67-1)

Safety Data

• Hazard Codes: Xn:Harmful
• Statements: R20/21/22:Harmful by inhalation, in contact with skin and if swallowed.; R36/37/38:Irritating to eyes, respiratory system
• Safety Statements: S26:In case of contact with eyes, rinse immediately with plenty of water and seek medical advice.; S36/37/39:Wear suitabl
• Hazardous Substances Data: 124276-67-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
1-(4-BROMOPHENYL)CYCLOPROPANECARBONITRILE, 97 is used as a key intermediate in the synthesis of various pharmaceutical compounds. Its unique structure and reactivity allow for the development of new drugs with specific therapeutic properties.
Used in Pesticide Industry:
In the pesticide industry, 1-(4-BROMOPHENYL)CYCLOPROPANECARBONITRILE, 97 is utilized as a building block for the creation of novel pesticides. Its chemical characteristics contribute to the formulation of effective and targeted pest control agents.
Used in Research and Development:
1-(4-BROMOPHENYL)CYCLOPROPANECARBONITRILE, 97 is employed as a research compound for exploring various synthesis techniques and understanding its chemical behavior. This helps in advancing the knowledge of organic chemistry and contributes to the discovery of new applications in different industries.

InChI:InChI=1/C11H9BrN2/c1-8-13-7-6-11(14-8)9-2-4-10(12)5-3-9/h2-7H,1H3

Upstream product

• 16532-79-9 4-Bromophenylacetonitrile 
• 107-04-0 1-Bromo-2-chloroethane 
• 96-49-1 [1,3]-dioxolan-2-one 
• 106-93-4 ethylene dibromide 
• 623-00-7 4-bromobenzenecarbonitrile 
• 56-37-1 N-benzyl-N,N,N-triethylammonium chloride 
• 179251-27-5 1-bromo-4-(cyclopropylidenemethyl)benzene 
• 1122-91-4 4-bromo-benzaldehyde 

Downstream Products

• 345965-52-8 1-(4-bromophenyl)cyclopropanecarboxylic acid 
• 867330-28-7 1-{4-[7-(2,6-dimethyl-phenyl)-5-methyl-benzo[1,2,4]triazin-3-ylamino]-phenyl}-cyclopropanecarbonitrile 
• 1147531-61-0 1-(4-bromophenyl)cyclopropane-1-carbaldehyde 
• 1215205-50-7 ethyl 1-(4-bromophenyl)cyclopropane-1-carboxylate 
• 1257214-56-4 N-[1-(4-bromo-phenyl)-cyclopropanecarbonyl]-methanesulfonamide 
• 1257214-59-7 N-{1-[4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenyl]-cyclopropanecarbonyl}-methanesulfonamide 
• 1257213-52-7 1-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]cyclopropane-1-carboxylic acid ethyl ester 
• 1280205-94-8 ethyl 1-(4'-(4-amino-3-methylisoxazol-5-yl)-[1,1'-biphenyl]-4-yl)cyclopropanecarboxylate 
• 1280205-95-9 1-[4'-(4-tert-Butoxycarbonylamino-3-methyl-isoxazol-5-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid ethyl ester 
• 1280206-27-0 1-[4'-(4-hydroxymethyl-3-methyl-isoxazol-5-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid ethyl ester 
• 1280206-29-2 1-[4'-(4-bromomethyl-3-methyl-isoxazol-5-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid ethyl ester 
• 1280732-40-2 1-[4'-(4-azidomethyl-3-methyl-isoxazol-5-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid ethyl ester 
• 1280732-41-3 1-{4'-[4-(4-Benzyl-[1,2,3]triazol-1-ylmethyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid ethyl ester 
• 1280206-91-8 1-[4'-(4-Formyl-3-methyl-isoxazol-5-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid ethyl ester 

Relevant articles and documents

Nickel-Catalyzed Favorskii-Type Rearrangement of Cyclobutanone Oxime Esters to Cyclopropanecarbonitriles

A nickel-catalyzed base-promoted rearrangement of cyclobutanone oxime esters to cyclopropanecarbonitriles was developed. The ring opening of cyclobutanone oxime esters occurs at the sterically less hindered side. A base-promoted nickelacyclobutane intermediate, formed in situ, is assumed to be involved in the formation of the product.

Preparation method of arylcyclopropane compound

The present invention discloses a method for preparing an arylcyclopropane compound, 1.0eq phenylacetonitrile and 1.1eq 1-bromo-2-chloroethane as the starting material, N, N- dimethylacetamide as a solvent, solvent dosage of 10V, plus 2.5eq sodium hydride

Photochemical Deracemization at sp3-Hybridized Carbon Centers via a Reversible Hydrogen Atom Transfer

A photochemical deracemization of 5-substituted 3-phenylimidazolidine-2,4-diones (hydantoins) is reported (27 examples, 69%-quant., 80–99% ee). The reaction is catalyzed by a chiral diarylketone which displays a two-point hydrogen bonding site. Mechanistic evidence (DFT calculations, radical clock experiments, H/D labeling) suggests the reaction to occur by selective hydrogen atom transfer (HAT). Upon hydrogen binding, one substrate enantiomer displays the hydrogen atom at the stereogenic center to the photoexcited catalyst allowing for a HAT from the substrate and eventually for its conversion into the product enantiomer. The product enantiomer is not processed by the catalyst and is thus enriched in the photostationary state.

Chiral Bidentate Boryl Ligand Enabled Iridium-Catalyzed Enantioselective C(sp3)-H Borylation of Cyclopropanes

We herein report an Ir-catalyzed enantioselective C(sp3)-H borylation of cyclopropanecarboxamides using a chiral bidentate boryl ligand for the first time. A variety of substrates with α-quaternary carbon centers could be compatible in this reaction to provide β-borylated products with good to excellent enantioselectivities. We have also demonstrated that the borylated products can be used as versatile precursors engaging in stereospecific transformations of C-B bonds, including the synthesis of a bioactive compound Levomilnacipran.

Electrophilic Bromolactonization of Cyclopropyl Diesters Using Lewis Basic Chalcogenide Catalysts

An efficient and regioselective electrophilic bromolactonization of cyclopropylmethyl diesters using triphenylphosphine sulfide (Ph3PS) or diphenyl selenide (Ph2Se) as the Lewis basic chalcogenide catalyst has been developed. It was observed that Ph3PS favored the formation of anti-diastereomer and yielded the multi-functional γ-lactones. Interestingly, the diastereoselectivity was reversed when using Ph2Se as a catalyst where the syn-product instead of the anti-product was favored. (Figure presented.).

Synthesis, SAR, and series evolution of novel oxadiazole-containing 5-lipoxygenase activating protein inhibitors: Discovery of 2-[4-(3-{(R)-1-[4-(2-amino-pyrimidin-5-yl)-phenyl]-1-cyclopropyl-ethyl}-[1,2,4]oxadiazol-5-yl)-pyrazol-1-yl]- N, N -dimethyl-acetamide (BI 665915)

The synthesis, structure-activity relationship (SAR), and evolution of a novel series of oxadiazole-containing 5-lipoxygenase-activating protein (FLAP) inhibitors are described. The use of structure-guided drug design techniques provided compounds that demonstrated excellent FLAP binding potency (IC50 4 synthesis in human whole blood (IC50 4 production.

Lewis Basic Sulfide Catalyzed Electrophilic Bromocyclization of Cyclopropylmethyl Amide

A Lewis basic sulfide catalyzed electrophilic bromocyclization of cyclopropylmethyl amide has been developed. The catalytic protocol is applicable to both 1,1- and 1,2-substituted cyclopropylmethyl amides, giving oxazolines and oxazines in good yields and excellent diastereoselectivity.

Cyclopropanation of substituted phenylacetonitriles or phenyl acetates

The present invention relates to a process for the cyclopropanation with ethylene carbonate or ethylene sulfate of a compound of formula (II): wherein G is -CN or -COOR in which R is a C1-C4 straight or branched alkyl X and Y are independently selected from the group consisting of hydrogen, fluorine, chlorine, bromine, iodine, R1O- and R1S- wherein R1 is C1-C4 straight or branched alkyl chain.

NOVEL PYRIMIDINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION INCLUDING SAME AS AN ACTIVE INGREDIENT

The present invention relates to a compound represented by formula (I) for inhibiting the activity of diacylglycerol O-acyltransferase type 1 (DGAT1), and pharmaceutically acceptable salts thereof, and a pharmaceutical composition comprising same as an active ingredient. The compound of the present invention may be used effectively in the treatment or prevention of a disease or condition mediated by the activity of DGAT1 such as obesity, type II diabetes, dyslipidemia, metabolic syndrome, and the like, without any adverse effects: wherein A, B, X, and R5 to R7 are the same as defined in the specification.

NOVEL PYRIMIDINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION INCLUDING SAME AS AN ACTIVE INGREDIENT

The present invention relates to a compound represented by formula (I) for inhibiting the activity of diacylglycerol O-acyltransferase type 1 (DGAT1), and pharmaceutically acceptable salts thereof, and a pharmaceutical composition comprising same as an active ingredient. The compound of the present invention may be used effectively in the treatment or prevention of a disease or condition mediated by the activity of DGAT1 such as obesity, type II diabetes, dyslipidemia, metabolic syndrome, and the like, without any adverse effects: wherein A, B, X, and R5 to R7 are the same as defined in the specification.